No Data
Truist Financial Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)
Express News | Intellia Therapeutics Inc : JP Morgan Cuts Target Price to $55 From $61
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Express News | RBC Capital Maintains Outperform on Intellia Therapeutics, Lowers Price Target to $54
Intellia Therapeutics Analyst Ratings
We Think Intellia Therapeutics (NASDAQ:NTLA) Needs To Drive Business Growth Carefully
10baggerbamm : why is anybody even bothering with this woman she's been negative year-to-date she is no conviction she gives price targets pie in the sky and if she really believed in them she would not be selling these companies she's full of shit she made money one year one time everything else has been a disaster
tankeng : yes this woman has problems and arrogant
OhNowGombie : Another quack you mean? Totally out of her gourd too